Skip to main content
Erschienen in: Neurotherapeutics 4/2013

01.10.2013 | Editorial

Looking Above but Not Beyond the Genome for Therapeutics in Neurology and Psychiatry: Epigenetic Proteins and RNAs Find a New Focus

verfasst von: Manuela Basso, Sama Sleiman, Rajiv R. Ratan

Erschienen in: Neurotherapeutics | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Excerpt

We welcome you to a special issue of Neurotherapeutics that highlights much of the exciting new thinking behind a burgeoning and therapeutically relevant topic—epigenetic proteins in psychiatric and neurological disease. It is now well established that expression of single genes or gene cassettes is determined by the interplay between transcription factors and epigenetic modulators. Epigenetics literally means “above the genome” and is defined by modifications of DNA, as well as chromatin that ultimately affect gene expression. Accordingly, epigenetic markers can be considered similar to punctuation marks in the English language. They define the beginning and the end of a gene; they structure the chromosomes; and they alter how the information is read, either activating or silencing transcription. …
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Waddington C. The epigenotype. Endeavour 1942;1:18–20. Waddington C. The epigenotype. Endeavour 1942;1:18–20.
2.
Zurück zum Zitat Riggs A, Russo V, Martienssen R. Epigenetic mechanisms of gene regulation. Cold Spring Harbor Laboratory Press, Plainview, NY, 1996. Riggs A, Russo V, Martienssen R. Epigenetic mechanisms of gene regulation. Cold Spring Harbor Laboratory Press, Plainview, NY, 1996.
4.
5.
Zurück zum Zitat Ptashne M. Faddish stuff: epigenetics and the inheritance of acquired characteristics. FASEB J 2013;27:1–2.PubMedCrossRef Ptashne M. Faddish stuff: epigenetics and the inheritance of acquired characteristics. FASEB J 2013;27:1–2.PubMedCrossRef
6.
Zurück zum Zitat Weng Y, An R,Shin J, Song H, Ming G. DNA Modifications and Neurological Disorders. Neurotherapeutics. 2013 Weng Y, An R,Shin J, Song H, Ming G. DNA Modifications and Neurological Disorders. Neurotherapeutics. 2013
7.
Zurück zum Zitat Schneider A, Chatterjee S, Bousiges O, Selvi BR, Swaminathan A, Cassel R, Blanc F, Kundu TK, Boutillier AL. Acetyltransferases (HATs) as targets for neurological therapeutics. Neurotherapeutics. 2013 Schneider A, Chatterjee S, Bousiges O, Selvi BR, Swaminathan A, Cassel R, Blanc F, Kundu TK, Boutillier AL. Acetyltransferases (HATs) as targets for neurological therapeutics. Neurotherapeutics. 2013
8.
Zurück zum Zitat Edward Holson E, Wagner FF, WeïWer M, Lewis MC. Small Molcule Inhibitors of Zinc-Dependent Histone Deacetylses (HDACs). Neurotherapeutics. 2013 Edward Holson E, Wagner FF, WeïWer M, Lewis MC. Small Molcule Inhibitors of Zinc-Dependent Histone Deacetylses (HDACs). Neurotherapeutics. 2013
9.
Zurück zum Zitat Langley B, Sauve A. Sirtuin Deacetylases as Therapeutic Targets in the Nervous Systems. Neurotherapeutics. 2013 Langley B, Sauve A. Sirtuin Deacetylases as Therapeutic Targets in the Nervous Systems. Neurotherapeutics. 2013
10.
Zurück zum Zitat Varela MA, Roberts TM, Wood MJA. Epigenetics and ncRNAs in brain function and diseasse: mechanisms and prospects for therapy. Neurotherapeutics. 2013 Varela MA, Roberts TM, Wood MJA. Epigenetics and ncRNAs in brain function and diseasse: mechanisms and prospects for therapy. Neurotherapeutics. 2013
11.
Zurück zum Zitat Qureshi IA, Mehler MF. Long non-coding RNAs: novel targets for nervous system disease diagnosis and Therapy. Neurotherapeutics. 2013 Qureshi IA, Mehler MF. Long non-coding RNAs: novel targets for nervous system disease diagnosis and Therapy. Neurotherapeutics. 2013
12.
Zurück zum Zitat Zhao Y, Jordan IK, Lunyak VV. Epigenetics Components of Aging in the Central Nervous System. Neurotherapeutics. 2013 Zhao Y, Jordan IK, Lunyak VV. Epigenetics Components of Aging in the Central Nervous System. Neurotherapeutics. 2013
13.
Zurück zum Zitat Lee J, Hwang YJ, Kim KY, Kowall KW, Ryu H. Epigenetic Mechanisms of Neurodegeneration in Huntington's Disease. Neurotherapeutics. 2013 Lee J, Hwang YJ, Kim KY, Kowall KW, Ryu H. Epigenetic Mechanisms of Neurodegeneration in Huntington's Disease. Neurotherapeutics. 2013
14.
Zurück zum Zitat Lunke S, El-Osta A. Applicability of histone deacetylase inhibition for the treatment of spinal muscular atrophy. Neurotherapeutics. 2013 Lunke S, El-Osta A. Applicability of histone deacetylase inhibition for the treatment of spinal muscular atrophy. Neurotherapeutics. 2013
15.
Zurück zum Zitat Helquist P, Maxfield F, Wiech NL, Wiest O. Treatment of Niemann-Pick Type C Disease by Histone Deacetylase Inhibitors. Neurotherapeutics. 2013 Helquist P, Maxfield F, Wiech NL, Wiest O. Treatment of Niemann-Pick Type C Disease by Histone Deacetylase Inhibitors. Neurotherapeutics. 2013
16.
Zurück zum Zitat Kaidery NA, Tarannum S, Thomas B. Order Epigenetic landscape of Parkinson's Disease: Emerging role in disease mechanisms and therapeutic modalities. Neurotherapeutics. 2013 Kaidery NA, Tarannum S, Thomas B. Order Epigenetic landscape of Parkinson's Disease: Emerging role in disease mechanisms and therapeutic modalities. Neurotherapeutics. 2013
17.
Zurück zum Zitat Sai Veerappan C, Sleiman SF, Coppola G. Epigenetics of Alzheimer's Diesease and Frontotemporal Dementia. Neurotherapeutics. 2013 Sai Veerappan C, Sleiman SF, Coppola G. Epigenetics of Alzheimer's Diesease and Frontotemporal Dementia. Neurotherapeutics. 2013
18.
Zurück zum Zitat Martin LJ, Wong M. Aberrant Regulation of DNA Methylation in Amyotrophic Lateral Sclerosis: A New Target of Disease Mechanisms. Neurotherapeutics. 2013 Martin LJ, Wong M. Aberrant Regulation of DNA Methylation in Amyotrophic Lateral Sclerosis: A New Target of Disease Mechanisms. Neurotherapeutics. 2013
19.
Zurück zum Zitat Mahgoub M, Monteggia L. Epigenetics and Psychiatry. Neurotherapeutics. 2013 Mahgoub M, Monteggia L. Epigenetics and Psychiatry. Neurotherapeutics. 2013
20.
Zurück zum Zitat Rangasamy S, D'Mello S, Narayanan V. Epigenetics, Autism Spectrum, and Neurodevelopmental Disorders. Neurotherapeutics. 2013 Rangasamy S, D'Mello S, Narayanan V. Epigenetics, Autism Spectrum, and Neurodevelopmental Disorders. Neurotherapeutics. 2013
21.
Zurück zum Zitat York EM, Petit A, Roskams AJI. Epigenetics of Neural Repair Following Spinal Cord Injury. Neurotherapeutics. 2013 York EM, Petit A, Roskams AJI. Epigenetics of Neural Repair Following Spinal Cord Injury. Neurotherapeutics. 2013
22.
Zurück zum Zitat Lindner R, Puttagunta R, Di Giovanni S. Epigenetic regulation of axon outgrowth and regeneration in CNS injury: the first steps forward. Neurotherapeutics. 2013 Lindner R, Puttagunta R, Di Giovanni S. Epigenetic regulation of axon outgrowth and regeneration in CNS injury: the first steps forward. Neurotherapeutics. 2013
23.
Zurück zum Zitat Garden G. Epigenetics and the Modulation of Neuroinflammation. Neurotherapeutics. 2013 Garden G. Epigenetics and the Modulation of Neuroinflammation. Neurotherapeutics. 2013
24.
Zurück zum Zitat Thompson JW, Dave KR, Young JI, Perez-Pinzon MA. Ischemic preconditioning alters the epigenetic profile of the brain from ischemic intolerance to ischemic tolerance. Neurotherapeutics. 2013 Thompson JW, Dave KR, Young JI, Perez-Pinzon MA. Ischemic preconditioning alters the epigenetic profile of the brain from ischemic intolerance to ischemic tolerance. Neurotherapeutics. 2013
25.
Zurück zum Zitat Baltan S, Morrison RS, Murphy SP. Novel protective effects of histone deacetylase inhibition on stroke and white matter ischemic injury. Neurotherapeutics. 2013 Baltan S, Morrison RS, Murphy SP. Novel protective effects of histone deacetylase inhibition on stroke and white matter ischemic injury. Neurotherapeutics. 2013
26.
Zurück zum Zitat Elder J, Sleiman SF, Basso B, Edwards D, Holson E, Ratan RR. Epigenetics of stroke recovery and rehabilitation: from polycomb to HDACs. Neurotherapeutics. 2013 Elder J, Sleiman SF, Basso B, Edwards D, Holson E, Ratan RR. Epigenetics of stroke recovery and rehabilitation: from polycomb to HDACs. Neurotherapeutics. 2013
27.
Zurück zum Zitat Brochier C, Langley B. Chromatin modifiations associated with DNA double strand breaks repair as potential targets for neurological disesases. Neurotherapeutics. 2013 Brochier C, Langley B. Chromatin modifiations associated with DNA double strand breaks repair as potential targets for neurological disesases. Neurotherapeutics. 2013
28.
Zurück zum Zitat Kulathu Y, Garcia FJ, Mevissen TE, Busch M, Arnaudo N, Carroll KS, et al. Regulation of A20 and other OTU deubiquitinases by reversible oxidation. Nat Commun 2013;4:1569.PubMedCrossRef Kulathu Y, Garcia FJ, Mevissen TE, Busch M, Arnaudo N, Carroll KS, et al. Regulation of A20 and other OTU deubiquitinases by reversible oxidation. Nat Commun 2013;4:1569.PubMedCrossRef
29.
30.
Zurück zum Zitat Banaszynski LA, Allis CD, Lewis PW. Histone variants in metazoan development. Dev Cell 2010;19:662–674.PubMedCrossRef Banaszynski LA, Allis CD, Lewis PW. Histone variants in metazoan development. Dev Cell 2010;19:662–674.PubMedCrossRef
31.
Zurück zum Zitat Banaszynski LA, Allis CD, Shechter D. Analysis of histones and chromatin in Xenopus laevis egg and oocyte extracts. Methods 2010;51:3–10.PubMedCrossRef Banaszynski LA, Allis CD, Shechter D. Analysis of histones and chromatin in Xenopus laevis egg and oocyte extracts. Methods 2010;51:3–10.PubMedCrossRef
Metadaten
Titel
Looking Above but Not Beyond the Genome for Therapeutics in Neurology and Psychiatry: Epigenetic Proteins and RNAs Find a New Focus
verfasst von
Manuela Basso
Sama Sleiman
Rajiv R. Ratan
Publikationsdatum
01.10.2013
Verlag
Springer US
Erschienen in
Neurotherapeutics / Ausgabe 4/2013
Print ISSN: 1933-7213
Elektronische ISSN: 1878-7479
DOI
https://doi.org/10.1007/s13311-013-0225-2

Weitere Artikel der Ausgabe 4/2013

Neurotherapeutics 4/2013 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.